Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · Apr 16, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a method called circulating tumor DNA (ctDNA) to help doctors find out how well cancer treatments are working, especially for patients with solid tumors like prostate, breast, and lung cancer. By detecting ctDNA early, the goal is to identify if cancer is coming back sooner, which could lead to better treatment options and improved outcomes for patients. The trial is currently recruiting participants, including healthy volunteers aged 18 and older.

If you decide to participate, you will help researchers understand how ctDNA can be used in everyday medical practice to guide cancer treatment decisions. This means that your involvement could contribute to future studies aimed at improving cancer care for everyone. It's important to note that only healthy individuals aged 18 or older can join, so if you're younger than that, you won't be eligible for this study. Your participation could play a key role in advancing personalized medicine for cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Eligible healthy donors will be at least 18 years of age.
• Exclusion Criteria:
• • Healthy donors younger than 18 years of age